EA201171140A1 - Сухая переработка ретигабина - Google Patents

Сухая переработка ретигабина

Info

Publication number
EA201171140A1
EA201171140A1 EA201171140A EA201171140A EA201171140A1 EA 201171140 A1 EA201171140 A1 EA 201171140A1 EA 201171140 A EA201171140 A EA 201171140A EA 201171140 A EA201171140 A EA 201171140A EA 201171140 A1 EA201171140 A1 EA 201171140A1
Authority
EA
Eurasian Patent Office
Prior art keywords
retigabin
dry
processing
relates
adhesion promoter
Prior art date
Application number
EA201171140A
Other languages
English (en)
Inventor
Катрин Римкус
Яна Пец
Original Assignee
Рациофарм Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рациофарм Гмбх filed Critical Рациофарм Гмбх
Publication of EA201171140A1 publication Critical patent/EA201171140A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к сухому способу получения оральных форм выпуска, в частности таблеток, содержащих ретигабин и усилитель адгезии. Далее, изобретение относится к прессованным промежуточным продуктам, содержащим ретигабин и усилитель адгезии. Наконец, изобретение относится к одно- или многодозным контейнерам, предпочтительно саше или упаковке Stick-Pack, содержащим промежуточный продукт по изобретению.
EA201171140A 2009-03-17 2010-03-17 Сухая переработка ретигабина EA201171140A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009013613A DE102009013613A1 (de) 2009-03-17 2009-03-17 Trockenverarbeitung von Retigabin
PCT/EP2010/001690 WO2010105822A2 (de) 2009-03-17 2010-03-17 Trockenverarbeitung von retigabin

Publications (1)

Publication Number Publication Date
EA201171140A1 true EA201171140A1 (ru) 2012-04-30

Family

ID=42136030

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171140A EA201171140A1 (ru) 2009-03-17 2010-03-17 Сухая переработка ретигабина

Country Status (6)

Country Link
US (1) US20120122973A1 (ru)
EP (1) EP2408424A2 (ru)
CA (1) CA2760040A1 (ru)
DE (2) DE102009013613A1 (ru)
EA (1) EA201171140A1 (ru)
WO (1) WO2010105822A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012008413A (es) * 2010-01-20 2012-08-15 Glaxo Group Ltd Composicion novedosa de retigabina.
CA2849546A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
IL293352A (en) * 2019-12-02 2022-07-01 Xenon Pharmaceuticals Inc A pediatric immediate-release formulation of the potassium channel opener azogabine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
GEP20053455B (en) 2000-03-08 2005-02-25 Awd Pharma Gmbh & Co Kg Pharmaceutical Preparations
US20020183395A1 (en) 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
DE20321314U1 (de) * 2002-05-31 2006-10-12 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
KR101405545B1 (ko) * 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
CA2731008A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
DE102009013611A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung

Also Published As

Publication number Publication date
US20120122973A1 (en) 2012-05-17
WO2010105822A3 (de) 2011-04-21
DE102009013613A1 (de) 2010-09-23
CA2760040A1 (en) 2010-09-23
EP2408424A2 (de) 2012-01-25
DE202010017303U1 (de) 2011-12-13
WO2010105822A2 (de) 2010-09-23

Similar Documents

Publication Publication Date Title
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
HK1214514A1 (zh) 神經浸潤抑制劑
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
EP2640431A4 (en) DOUBLE CROSSLINKING PROCESS TO PROMOTE THE POST-IMPLANTATION DURABILITY OF BIO-PROSTHETIC TISSUES
MY160456A (en) Benzodiazepine bromodomain inhibitor
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
MY158438A (en) Antibodies against human angiopoietin 2
MX2011003473A (es) Composiciones para el cuidado bucal.
EP2410855A4 (en) PROCESS FOR THE PREPARATION OF ALOGLIPTIN
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
WO2012016683A3 (en) Oral dosage form of pregabalin
EA201171140A1 (ru) Сухая переработка ретигабина
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PL2320927T3 (pl) Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
WO2013015579A3 (ko) 콜라겐 및 히알루론산 유도체를 포함하는 의료용 복합 생체 소재
CL2013000831A1 (es) Metodo para la determinacion del contenido de alergenos de una composicion.
EP2639230A4 (en) PROLINAMID DERIVATIVE AS THROMBIN EMBROIDER, METHOD FOR THE PRODUCTION THEREOF AND THE APPLICATION THEREOF
MY158910A (en) Surface modified silicic acid semi-gels
MX348786B (es) Agentes osmoticos de polisacarido esterificado.
WO2011069045A3 (en) Synthesis of syrbactin proteasome inhibitors
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.